Edition:
United States

Neovacs SA (ALNEV.PA)

ALNEV.PA on Paris Stock Exchange

0.95EUR
16 Jan 2017
Change (% chg)

€0.02 (+2.15%)
Prev Close
€0.93
Open
€0.93
Day's High
€0.96
Day's Low
€0.90
Volume
882,888
Avg. Vol
530,445
52-wk High
€1.56
52-wk Low
€0.66

ALNEV.PA

Chart for ALNEV.PA

About

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company... (more)

Overall

Beta: 0.70
Market Cap(Mil.): €39.96
Shares Outstanding(Mil.): 42.97
Dividend: --
Yield (%): --

Financials

  ALNEV.PA Industry Sector
P/E (TTM): -- 46.47 30.92
EPS (TTM): -0.16 -- --
ROI: -100.09 -0.87 14.82
ROE: -181.68 -0.56 16.24

BRIEF-Neovacs signs production partnership with 3P Biopharmaceuticals

* Neovacs signs production partnership with 3p biopharmaceuticals, a leading gmp producer of biological drugs Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 23 2016

BRIEF-Neovacs acquires Interferon Alpha manufacturing technology

* Acquires interferon alpha manufacturing technology from AMEGABIOTECH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 15 2016

BRIEF-Neovacs enrolls first US patient in phase IIb study of IFNa Kinoid for SLE treatment

* Neovacs enrolls the first US patient in phase IIb study of IFNa Kinoid for treatment of Systemic Lupus Erythematosus (SLE) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 07 2016

BRIEF-Neovacs announces cooperation agreement with the immunology of diabetes department at the Paris Cochin hospital

* Cooperation agreement with the immunology of diabetes department at the Paris Cochin hospital

Oct 12 2016

BRIEF-Neovacs H1 net loss widens to 6.8 mln euros

* H1 net loss is 6.8 million euros ($7.6 million) versus a loss of 4.9 million euros a year ago

Sep 30 2016

BRIEF-Stellar Biotechnologies, Neovacs announce formation of new company Neostell S.A.S. in France

* Stellar Biotechnologies and Neovacs announce formation of new company Neostell S.A.S. In France

Jul 19 2016

BRIEF-Neovacs and Stellar Biotechnologies launch Neostell, joint venture to manufacture Kinoids

* Neovacs and Stellar Biotechnologies announce launch of Neostell, joint venture to manufacture Kinoids

Jul 19 2016

Earnings vs. Estimates